Summary
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing its oncology program. SL-325's Phase 1 data show strong safety, low immunogenicity (3.7% ADA rate), and durable receptor occupancy, supporting quarterly dosing potential. STTK is fully funded through Phase 2b efficacy readout, with cash runway into 2029 despite significant dilution; valuation trades at a forward price-to-book discount.
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Shattuck Labs Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| AF Anthony Fasano Clark Estates INC/NY | 1.43M | $3.29M | $7.71M | $4.42M | 134.35% |
| BG Bart Gancher Intech Investment Management LLC | 10,594 | $72,568.9 | $58,584.82 | -$13,984.08 | -19.27% |
| CD Charlie Durham Sterling Capital Management LLC | 348 | $2,415 | $1,854.84 | -$560.16 | -23.2% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.17M | $4.73M | $6.47M | $1.74M | 36.8% |
| NM Nir Messafi Deep Track Capita LLP | 3.71M | $25.39M | $20.24M | -$5.15M | -20.29% |
Shattuck Labs Inc. (STTK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Shattuck Labs Inc. ever had a stock split?
Shattuck Labs Inc. Profile
| Biotechnology Industry | Healthcare Sector | Taylor H. Schreiber CEO | NASDAQ (NGS) Exchange | 82024L103 CUSIP |
| US Country | 40 Employees | - Last Dividend | - Last Split | 9 Oct 2020 IPO Date |
Overview
Shattuck Labs, Inc. is a forward-thinking biotechnology company focused on the clinical-stage development of innovative therapeutics. Founded in 2016 and based in Austin, Texas, the company dedicates its research and development efforts to tackling some of the most challenging health issues today, primarily cancer and autoimmune diseases. By leveraging cutting-edge technology and scientific research, Shattuck Labs aims to create treatments that can significantly improve patient outcomes in areas where traditional therapies have fallen short.
Products and Services
- SL-172154
This lead product candidate exemplifies Shattuck Labs' innovative approach to medical treatments. Currently in Phase 1 clinical trials, SL-172154 is being developed for patients with ovarian, fallopian tube, and peritoneal cancers. This pioneering treatment represents the forefront of the company’s commitment to addressing some of the most pressing needs within oncology. By focusing on these specific cancers, Shattuck Labs underscores its dedication to contributing significant advancements in the treatment and understanding of these diseases.
Contact Information
